- Home
- NGNE vs FERA Comparison
NGNE vs FERA Comparison
Compare NGNE & FERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- FERA
- Stock Information
- Founded
- NGNE 2003
- FERA 2024
- Country
- NGNE United States
- FERA Cayman Islands
- Employees
- NGNE N/A
- FERA N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- FERA
- Sector
- NGNE Health Care
- FERA
- Exchange
- NGNE Nasdaq
- FERA Nasdaq
- Market Cap
- NGNE 325.3M
- FERA 317.4M
- IPO Year
- NGNE N/A
- FERA 2025
- Fundamental
- Price
- NGNE $18.48
- FERA $10.13
- Analyst Decision
- NGNE Strong Buy
- FERA
- Analyst Count
- NGNE 7
- FERA 0
- Target Price
- NGNE $41.86
- FERA N/A
- AVG Volume (30 Days)
- NGNE 108.3K
- FERA 3.0
- Earning Date
- NGNE 08-11-2025
- FERA 01-01-0001
- Dividend Yield
- NGNE N/A
- FERA N/A
- EPS Growth
- NGNE N/A
- FERA N/A
- EPS
- NGNE N/A
- FERA N/A
- Revenue
- NGNE N/A
- FERA N/A
- Revenue This Year
- NGNE N/A
- FERA N/A
- Revenue Next Year
- NGNE N/A
- FERA N/A
- P/E Ratio
- NGNE N/A
- FERA N/A
- Revenue Growth
- NGNE N/A
- FERA N/A
- 52 Week Low
- NGNE $6.88
- FERA $10.00
- 52 Week High
- NGNE $74.49
- FERA $10.60
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- FERA N/A
- Support Level
- NGNE $19.59
- FERA N/A
- Resistance Level
- NGNE $20.46
- FERA N/A
- Average True Range (ATR)
- NGNE 1.23
- FERA 0.00
- MACD
- NGNE -0.20
- FERA 0.00
- Stochastic Oscillator
- NGNE 13.37
- FERA 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.